News

October 18, 2019October 18, 2019

NICE Favors Adding Rubraca to NHS England to Treat Relapsed Ovarian Cancer

News

The U.K.’s National Institute for Health and Care Excellence, widely known as NICE, is recommending that Clovis Oncology‘s Rubraca (rucaparib) be available as a maintenance therapy for women with recurrent ... Read more

October 16, 2019October 16, 2019

Zejula Prolongs Life Without Disease Worsening in Newly Diagnosed Advanced Ovarian Cancer, Trial Shows

www.zejula.com

October 14, 2019October 14, 2019

Fujifilm SonoSite, AI2 Incubator Work on Using AI to Improve Ultrasound Imaging

News

Fujifilm SonoSite is collaborating with the Allen Institute of Artificial Intelligence (AI2) Incubator to use artificial intelligence to improve the accuracy of ultrasound images, the standard way to detect ... Read more

October 9, 2019

Navicixizumab Earns FDA Fast Track Designation for Heavily Pretreated Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to navicixizumab (OMP-305B83) as a potential therapy for heavily pretreated ovarian cancer, Mereo BioPharma, the therapy’s developer, announced. Fast ... Read more

October 7, 2019October 7, 2019

Mirvetuximab Soravtansine Effectively Delays Disease Progression in FRα-high Ovarian Cancers, Analysis Finds

News

ImmunoGen’s investigational therapy mirvetuximab soravtansine effectively delays disease progression in women with ovarian cancer who have high levels of the folate receptor alpha (FRα) protein, compared with chemotherapy, according ... Read more

October 4, 2019October 4, 2019

Adding Veliparib Extends Time Without Disease Progression in Metastatic Ovarian Cancer, Phase 3 Trial Finds

News

Using veliparib in combination with chemotherapy as first-line and then maintenance therapy post-surgery significantly extended the time without disease progression in women with newly diagnosed metastatic high-grade serous (HGS) ... Read more

October 2, 2019October 3, 2019

Gynecological Cancer Patients with Specific Wnt Mutations and High DKK1 Levels Respond Better to DKN-01, Trial Results Show

News

Leap Therapeutics’s investigational therapy DKN-01, alone or in combination with Taxol (paclitaxel), leads to significantly better responses in women with relapsed endometrial or ovarian cancer whose tumors have high levels of the ... Read more

September 30, 2019October 16, 2019

Fertility-Sparing Surgery Equally Effective as Radical Surgery in Early Stage Ovarian Cancer, Study Finds

News

Surgical treatment aimed at preserving fertility is just as effective, in terms of survival, as more aggressive surgery in treating early-stage ovarian cancer, a new study suggests. The study, ... Read more

September 27, 2019

Rubraca Extends Time to Disease Progression in Recurrent OC, Regardless of Chemo Response, Analysis Shows

News

Maintenance treatment with Clovis Oncology’s Rubraca (rucaparib) extends the time until disease progression in women with recurrent ovarian cancer, exploratory analysis from a Phase 3 trial shows. This occurs regardless ... Read more

September 25, 2019

Spherix Acquires Rights to Anthrax Toxin Altered to Target Ovarian Cancer

News

Spherix announced that it has closed an exclusive option agreement to license PrAg-PAS, an anthrax-based potential therapy for ovarian cancer developed by scientists at the University of Maryland at Baltimore ... Read more

Pin It on Pinterest